A new long-acting sustained-release human growth hormone LAPSrhGH, which Hanmi Pharmaceutical has been developing, was presented at an international medical organization.
Hanmi Pharmaceutical announced the findings of Phase 1 clinical trials with LAPSrhGH in Korea, and the interim results of Phase 2 in multiple countries at the Endocrine Society (ENDO) being held in San Diego, U.S., from March 5 to 8.
LAPSrhGH is a long-acting human growth hormone candidate for the treatment of growth hormone deficiency, developed as a bi-weekly or monthly administration therapy using Hanmi's Lapscovery technology, which prolongs the duration of the drug effects of short-acting biologics. It noticeably relieves the pain of patients when injected.
According to the presentations, Hanmi Pharmaceutical confirmed the safety and duration of more than a week in Phase 1 clinical trials on Korean healthy adult males when injected with a single dose.
Also, the company confirmed the safety, longer duration, and suitable doses for the future development of LAPSrhGH through ongoing Phase 2 clinical studies on adult patients suffering from growth hormone deficiency in 22 medical institutions, not only in Korea, but also in 8 Eastern European countries.
Kang Ja-hoon, managing director of the clinical study team at Hanmi Pharmaceutical, said, “As the new drug of long-acting sustained-release human growth hormone can prolong the injection cycle to more than a week and drastically relieve the injection pain compared to existing products, we expect that it will improve patients' quality of life dramatically.”